Literature DB >> 18570408

Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.

Elisabetta Sabini1, Saugata Hazra, Manfred Konrad, Arnon Lavie.   

Abstract

Purine nucleoside analogues of medicinal importance, such as cladribine, require phosphorylation by deoxycytidine kinase (dCK) for pharmacological activity. Structural studies of ternary complexes of human dCK show that the enzyme conformation adjusts to the different hydrogen-bonding properties between dA and dG and to the presence of substituent at the 2-position present in dG and cladribine. Specifically, the carbonyl group in dG elicits a previously unseen conformational adjustment of the active site residues Arg104 and Asp133. In addition, dG and cladribine adopt the anti conformation, in contrast to the syn conformation observed with dA. Kinetic analysis reveals that cladribine is phosphorylated at the highest efficiency with UTP as donor. We attribute this to the ability of cladribine to combine advantageous properties from dA (favorable hydrogen-bonding pattern) and dG (propensity to bind to the enzyme in its anti conformation), suggesting that dA analogues with a substituent at the 2-position are likely to be better activated by human dCK.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570408      PMCID: PMC2636677          DOI: 10.1021/jm800134t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  X-ray-induced debromination of nucleic acids at the Br K absorption edge and implications for MAD phasing.

Authors:  E Ennifar; P Carpentier; J L Ferrer; P Walter; P Dumas
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-07-20

Review 2.  Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.

Authors:  R S Goody; B Müller; T Restle
Journal:  FEBS Lett       Date:  1991-10-07       Impact factor: 4.124

3.  Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.

Authors:  T L Hughes; T M Hahn; K K Reynolds; D S Shewach
Journal:  Biochemistry       Date:  1997-06-17       Impact factor: 3.162

4.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities.

Authors:  R M Esnouf
Journal:  J Mol Graph Model       Date:  1997-04       Impact factor: 2.518

5.  The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation.

Authors:  Yan Zhang; John A Secrist; Steven E Ealick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-01-18

6.  A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.

Authors:  J C White; R L Capizzi
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

7.  Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

Authors:  H Kawasaki; C J Carrera; L D Piro; A Saven; T J Kipps; D A Carson
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

8.  Nucleotide specificity of human deoxycytidine kinase.

Authors:  D S Shewach; K K Reynolds; L Hertel
Journal:  Mol Pharmacol       Date:  1992-09       Impact factor: 4.436

9.  Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2007-05-27       Impact factor: 7.446

10.  Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Stephen K Burley; Arnon Lavie
Journal:  Nucleic Acids Res       Date:  2006-12-07       Impact factor: 16.971

View more
  6 in total

1.  Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues .

Authors:  Saugata Hazra; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2010-08-10       Impact factor: 3.162

2.  Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release.

Authors:  Saugata Hazra; Andrzej Szewczak; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2011-03-16       Impact factor: 3.162

3.  Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.

Authors:  Julian Nomme; Jennifer M Murphy; Ying Su; Natasha D Sansone; Amanda L Armijo; Steven T Olson; Caius Radu; Arnon Lavie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-12-24

4.  The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): implications for the development of dCK-activated acyclic guanine analogues.

Authors:  Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

5.  Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase.

Authors:  Saugata Hazra; Elisabetta Sabini; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2009-02-17       Impact factor: 3.162

Review 6.  Highlights in Resistance Mechanism Pathways for Combination Therapy.

Authors:  João M A Delou; Alana S O Souza; Leonel C M Souza; Helena L Borges
Journal:  Cells       Date:  2019-08-30       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.